CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 20861165.
- Also identified by DOI 10.1158/1078-0432.CCR-10-2244.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CD44, a cancer stem cell (CSC)-related surface marker, correlates with local control after radiotherapy of early laryngeal cancer. For the first time, a CSC-related marker has been functionally validated for radiotherapy in patients. CD44 expression bears the potential to predict the outcome of radiotherapy by assessment of CSC density.
Medical subject headings
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Hyaluronan Receptors
- Neoplastic Stem Cells